journal article·2024-04Open access

Self‐Assembled Multiepitope Nanovaccine Provides Long‐Lasting Cross‐Protection against Influenza Virus

Jiaojiao Nie, Qingyu Wang, Chenxi Li, Yongfei Zhou, Xin Yao, Lipeng Xu, Yaotian Chang, Fan Ding, Lulu Sun, Li Zhan, Lvzhou Zhu, Kunpeng Xie, Xu Wang, Yuhua Shi, Qi Zhao, Yaming Shan

Advanced Healthcare Materials· Volume 13· Issue 10

Abstract

Abstract Seasonal influenza vaccines typically provide strain‐specific protection and are reformulated annually, which is a complex and time‐consuming process. Multiepitope vaccines, combining multiple conserved antigenic epitopes from a pathogen, can trigger more robust, diverse, and effective immune responses, providing a potential solution. However, their practical application is hindered by low immunogenicity and short‐term effectiveness. In this study, multiple linear epitopes from the conserved stem domain of hemagglutinin and the ectodomain of matrix protein 2 are combined with the Helicobacter pylori ferritin, a stable self‐assembled nanoplatform, to develop an influenza multiepitope nanovaccine, named MHF. MHF is prokaryotically expressed in a soluble form and self‐assembles into uniform nanoparticles. The subcutaneous immunization of mice with adjuvanted MHF induces cross‐reactive neutralizing antibodies, antibody‐dependent cell‐mediated cytotoxicity, and cellular immunity, offering complete protection against H3N2 as well as partial protection against H1N1. Importantly, the vaccine cargo delivered by ferritin triggers epitope‐specific memory B‐cell responses, with antibody level persisting for over 6 months post‐immunization. These findings indicate that self‐assembled multiepitope nanovaccines elicit potent and long‐lasting immune responses while significantly reducing the risk of vaccine escape mutants, and offer greater practicality in terms of scalable manufacturing and genetic manipulability, presenting a promising and effective strategy for future vaccine development.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Influenza Virus Research Studies · Lipid Membrane Structure and Behavior · interferon and immune responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

National Engineering Laboratory for AIDS Vaccine School of Life Sciences Jilin University 2699 Qianjin Street Changchun 130012 China

Cancer Centre, Faculty of Health Sciences University of Macau Taipa Macau 519000 China

MoE Frontiers Science Center for Precision Oncology University of Macau Taipa Macau SAR 519000 China

Key Laboratory for Molecular Enzymology and Engineering The Ministry of Education School of Life Sciences Jilin University 2699 Qianjin Street Changchun 130012 China

Funding

Changchun Science and Technology Planning Project

References (51)

Show source-provided references
1. 10.1101/cshperspect.a03835610.1101/cshperspect.a038356 ↗
2. 10.1016/S1473-3099(18)30364-510.1016/S1473-3099(18)30364-5 ↗
3. 10.1038/s41572-018-0002-y10.1038/s41572-018-0002-y ↗
4. 10.1093/infdis/jiy63310.1093/infdis/jiy633 ↗
5. 10.1186/s12929-020-0626-610.1186/s12929-020-0626-6 ↗
6. 10.1038/s41573-019-0056-x10.1038/s41573-019-0056-x ↗
7. 10.1038/s41591-018-0340-z10.1038/s41591-018-0340-z ↗
8. 10.1016/j.celrep.2015.06.00510.1016/j.celrep.2015.06.005 ↗
9. 10.1093/infdis/jiy10310.1093/infdis/jiy103 ↗
10. 10.3390/v1306097310.3390/v13060973 ↗
11. 10.1038/s41385-022-00497-910.1038/s41385-022-00497-9 ↗
12. 10.1021/acsnano.1c0407810.1021/acsnano.1c04078 ↗
13. 10.1002/adhm.20190117610.1002/adhm.201901176 ↗
14. 10.1371/journal.pone.011952010.1371/journal.pone.0119520 ↗
15. 10.1002/smll.20170320710.1002/smll.201703207 ↗
16. 10.1186/s12929-019-0572-310.1186/s12929-019-0572-3 ↗
17. 10.1093/cid/ciz92710.1093/cid/ciz927 ↗
18. 10.3390/vaccines903025710.3390/vaccines9030257 ↗
19. 10.1371/journal.ppat.100570210.1371/journal.ppat.1005702 ↗
20. 10.1371/journal.ppat.100079610.1371/journal.ppat.1000796 ↗
21. 10.1016/j.cell.2016.05.07310.1016/j.cell.2016.05.073 ↗
22. 10.1016/j.compbiomed.2020.10396710.1016/j.compbiomed.2020.103967 ↗
23. 10.3389/fvets.2020.57199910.3389/fvets.2020.571999 ↗
24. 10.1002/advs.20210031610.1002/advs.202100316 ↗
25. Sun C. · J. Virol. · 2022 · 9610.1128/jvi.00383-22 ↗
26. 10.1016/j.jconrel.2018.02.04210.1016/j.jconrel.2018.02.042 ↗
27. 10.1038/s41541-022-00547-010.1038/s41541-022-00547-0 ↗
28. 10.1038/nm.392710.1038/nm.3927 ↗
29. 10.1038/s41590-018-0305-x10.1038/s41590-018-0305-x ↗
30. 10.1002/JLB.6A1021-535R10.1002/JLB.6A1021-535R ↗
31. 10.1126/sciimmunol.aba646610.1126/sciimmunol.aba6466 ↗
32. 10.1186/s12951-021-01229-010.1186/s12951-021-01229-0 ↗
33. 10.1016/j.immuni.2020.11.01510.1016/j.immuni.2020.11.015 ↗
34. 10.1039/C9BM00098D10.1039/C9BM00098D ↗
35. 10.1038/nature1220210.1038/nature12202 ↗
36. 10.1126/scitranslmed.ade479010.1126/scitranslmed.ade4790 ↗
37. 10.1182/blood-2008-05-15701610.1182/blood-2008-05-157016 ↗
38. 10.1038/s41385-019-0243-410.1038/s41385-019-0243-4 ↗
39. 10.1073/pnas.180571311510.1073/pnas.1805713115 ↗
40. 10.1038/s41392-021-00797-910.1038/s41392-021-00797-9 ↗
41. 10.1128/mBio.01408-1810.1128/mBio.01408-18 ↗
42. 10.1038/mt.2014.3310.1038/mt.2014.33 ↗
43. 10.1126/sciimmunol.abq764710.1126/sciimmunol.abq7647 ↗
44. 10.1172/jci.insight.13164410.1172/jci.insight.131644 ↗
45. 10.1039/D1NR08460G10.1039/D1NR08460G ↗
46. 10.1007/s12274-023-5395-610.1007/s12274-023-5395-6 ↗
47. 10.1038/s41467-017-02725-410.1038/s41467-017-02725-4 ↗
48. 10.1038/cmi.2017.4310.1038/cmi.2017.43 ↗
49. 10.1038/ni.182110.1038/ni.1821 ↗
50. 10.1016/j.xcrm.2021.10044810.1016/j.xcrm.2021.100448 ↗
51. 10.1016/j.bioactmat.2022.03.02610.1016/j.bioactmat.2022.03.026 ↗